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Importance: Cerebral palsy (CP) is considered a paediatric condition despite most people 
living into adulthood. Due to this we lack evidence in adults with CP, this includes a paucity 
of research examining mental health in this population. 
Objectives: Determine the risk of depression and anxiety in adults with a diagnosis of CP 
compared with an age-, sex-, and practice-matched reference group of adults without CP, using 
primary care data. 
Design, setting and participants: Retrospective longitudinal cohort study set in UK primary 
care. Data were analysed using Cox proportional hazards regression analyses adjusted for 
chronic conditions and visits to their physician. The study period ran from 1987 to 2015. 
Data for 1,705 adults aged 18 or older with CP and 5,115 matched adults who did not have CP 
were extracted. CP was identified using diagnostic codes, and each person with CP was 
compared with 3 age, sex and practice matched controls.  
Exposure: Diagnosis of CP, with a second analysis accounting for co-morbidity of intellectual 
disability (ID). 
Main outcomes: Time to diagnosis for depression or anxiety following the date of entry into 
the study in adults with CP (with and without ID) when compared with matched controls. 
Results: The mean age of the CP and matched group was 33.3 and 46.8% (n=798) were female. 
People with CP had an increased adjusted hazard of depression (HR 1.28, 95% CI: 1.09-1.51) 
and anxiety (HR 1.40, 95% CI: 1.21-1.63) when compared with the matched reference group. 
When we accounted for ID co-morbidity there were 363 adults with CP who also had ID (mean 
age 32.1, 47.6% (n=159) female) and 1342 adults with CP who did not have ID (mean age 
33.6, 43.8% (n=639) female). Only those people with CP and no co-morbid ID had a higher 
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risk of incident depression (HR 1.44: 95% CI 1.20-1.72) and anxiety (HR 1.55: 95% CI 1.28-
1.87) than their matched controls.  
Conclusions: The results demonstrate that adults with CP have an increased risk of depression 
or anxiety. In particular, our results indicate that this association is driven largely by those 
individuals with CP with no co-occurring ID. Future work is needed in community-based 
























• Questions: What is the risk of depression and anxiety in adults with cerebral palsy when 
compared with age, sex and area matched controls? 
Findings: Adults with cerebral palsy have an increased risk of depression and anxiety 
when compared with age, sex and practice-matched controls. When we also accounted 
for intellectual disability co-morbidity we found that it was only those adults who had 
cerebral palsy with no intellectual disability that had an increased risk of depression 
and anxiety. 
Meaning: Adults with cerebral palsy have a higher risk of developing anxiety and 

















Cerebral palsy (CP) is the umbrella term used for a heterogeneous group of etiologies that occur 
to a developing foetal or infant brain (1). People diagnosed with CP have similar hallmark 
symptoms including issues with movement, coordination, posture, and balance (1, 2). These 
motor disturbances can also be co-morbid with other issues such as behavioral disturbance, 
cognitive difficulties, communication difficulties, sensory impairments, epilepsy, and 
intellectual disability (ID) (1).It is estimated that CP affects 2-3 in 1,000 live births, and 
approximately 1 in 400 people in the UK live with CP (3, 4).  
Due to the fact that the CP develops and is diagnosed in early childhood (5) it is often 
considered a paediatric condition. However, CP is a lifelong condition with the majority of 
children living into adulthood, depending on the severity of the condition and associated 
physical co-morbidities (6, 7). There is evidence that as people with CP transition into and 
throughout adulthood, there can be deterioration in physical functioning, and a rise in 
secondary health conditions (8, 9). The experience of ageing with CP is therefore likely to be 
linked with different psychological, social and medical issues than those experienced through 
having CP as a child. However, most evidence on mental health and CP is focused on children 
(10), which cannot be generalized to adult populations. 
Depression and anxiety are two of the most common mental illnesses in the general 
population (11). and there is substantial evidence that living with a long-term condition or 
disability is associated with a two-to-three fold increase in the likelihood of being diagnosed 
with depression (12, 13) or anxiety (14). However, there is relatively little research specifically 
examining mental health outcomes in adults with CP. 
Existing evidence indicates that 20-25% of adults with CP have clinically significant 
levels of depressive symptoms (15, 16). Furthermore, a recent clinical study in 501 adults with 
CP from a clinic in the USA found that 39% of patients met criteria for a diagnosis of anxiety 
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disorder, and 31% met criteria for a diagnosis of major depression (17). A recent paper that 
compared the prevalence of depression and anxiety in adults with CP to the general population 
found that adults with CP were more likely to experience depression, but not anxiety, than the 
general population (18). However, this work was cross-sectional and there is a need for 
longitudinal work to systematically investigate whether CP is associated with an increased risk 
of anxiety or depression in adulthood. 
However, the association between depression, anxiety and CP could be modified by co-
morbid intellectual disability (ID). Approximately a third of people with CP also experience 
co-morbid ID (2); however, ID has been associated with difficulties correctly identifying 
common mental illness due to diagnostic overshadowing (19). Diagnostic overshadowing can 
happen in people with ID because distress (including anxiety and depression) can present as 
challenging behaviours instead of the symptoms we typically associate with depression and 
anxiety (20, 21). In other words, the challenging behaviours overshadow the correct diagnosis 
of mental illness. This could mean that although we might expect the incidence of anxiety and 
depression to be higher in adults with CP, it is also important to account for the presence of ID. 
The aim of this paper was to determine the incidence of depression and anxiety in adults 
with CP, as compared with age-, sex-, and general practice-matched controls using primary 
care data from the United Kingdom. We also sought to determine whether the presence of co-
morbid ID impacted on the associations between CP and incident depression and anxiety. 
 
Methods 
Clinical Practice Research Datalink (CPRD) database 
Data for this study was taken from the CPRD primary care database. This database reflects the 
collection of consultation data from consenting general practices throughout the UK, and it 
covers 6.9% of the UK population with active data available for 4.4 million people (22). 
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Previous work has shown the population contained within the CPRD database are 
representative of the UK population (22). Collected data includes clinical events, prescriptions, 
referrals and hospital admissions. Formal data collection commenced in 1987 and data for this 
study was from the period 1 January 1987 to 30 November 2015. CPRD obtained ethical 
approval from a National Research Ethics Service Committee which allows researchers to 
access anonymised data for observational studies upon the approval of a protocol to an 
Independent Scientific Advisory Committee (ISAC).  
Participants 
Any patient aged 18 or older who had at least one record of CP during the study period, and 
during a period in which their data was considered research-standard  (i.e., their data were 
determined by CPRD to be of sufficient quality for research assessment), was included as a 
case of CP. CPRD checks data to ensure it is research standard by determining whether the 
patient-level data consists of valid registration dates and that the data provided by the practice 
has been continuous (22). 
Diagnoses were identified using Read codes which are alphanumeric codes used in UK 
healthcare to reference a Read term that captures the reason for consultation (e.g., the Read 
code F2B..00 refers to the Read term ‘Cerebral Palsy’) A diagnosis of CP was identified by 
one of 22 Read codes for CP which were created by the senior investigator (JR) and checked 
by other CP experts (see Appendix A). The index date, i.e. the start of follow-up, was defined 
as the latest of: (1) The date that the patient registered with their General Practitioner (GP); (2) 
The date that their data became research-standard; or (3) The year in which they turned 18. 
Initially 14,788 patients with CP were identified. Following exclusions based on age (<18 years 
old, n=2,510), a Read code for CP not occurring within the study period and/or a period when 
data were research-standard (n=10,038), and potentially inaccurate codes (n=535), a sample of 
1,705 patients with CP were included within the main analysis. 
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Each patient with CP was matched to three patients who did not have CP for age (within 
± 3 years), sex and practice. Practice was used as an indicator of area-level socioeconomic 
status, as CPRD uses area-level deprivation as an indicator of socioeconomic position (23). In 
total 5,115 matched controls were identified, and these matched controls acted as the reference 
(comparison) group for our main analyses. The index date for each patient without CP was set 
as the same date as their respective matched CP case. 
In additional analyses, we also examined the impact of ID co-morbidity on the 
incidence of anxiety and depression in adults with CP. These cases were identified using a list 
of Read codes provided by the Cambridge primary care unit (24). For these additional analyses, 
we split the CP group into CP patients with no ID co-morbidity (CPnoID) and CP patients with 
ID (CP+ID). 
Identification of depression and anxiety 
Cases of depression and anxiety were identified using the read codes developed by John et al. 
(25) and the Cambridge Primary Care Unit (24). Where the codes could refer to a possible case 
of depression (e.g., mood disorders or depression-related symptoms) or anxiety (e.g., worrying) 
these were only considered this a case of depression where the patient was also given 
antidepressants and/or anxiolytic medication (see Appendix A for a list of Read codes). We 
excluded those codes that referred to a history of depression or anxiety, depression or anxiety 
remission, interim reviews or medication reviews (as we wanted to ascertain the first event of 
depression and anxiety after the index date). The date of the first event of depression was 
identified following the index date. Where no event of depression occurred, participants were 
followed-up until the earliest of the following and treated as censored: transfer out of CPRD, 
death or end of follow-up period. This was repeated for anxiety. 
Identification of ID 
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Read codes developed by the Cambridge primary care unit (24) were used to identify people 
with ID. These Read codes included specific conditions associated with ID such as fragile X 
syndrome and Down’s syndrome alongside other synonyms for ‘learning disability’ and 
‘intellectual disability’ (24). 
Potential confounders 
As other chronic conditions and GP visits could be linked with an increased likelihood of 
detecting incident anxiety and depression we adjusted our analyses for these confounders. We 
used the Read codes proposed by the Cambridge primary care unit (24) to identify the following 
chronic conditions: Heart disease (myocardial infarction, coronary heart disease and/or 
arrhythmia); lung disease (chronic obstructive pulmonary disease, chronic bronchitis and/or 
asthma); pain conditions (four or more prescriptions of pain medication); epilepsy and diabetes. 
We also identified Read codes for osteoarthritis based on ICD-9 and ICD-10 read terms. Finally 
we identified the average number of GP visits per year, (0-2 visits per year, 2-11.9 visits per 
year or ≥12 visits per year). We used 12 visits per year as an indicator for frequent GP 
consultations as has been done in previous work (26). 
For each potential confounder we identified only those cases that occurred before the 
event date (i.e., depression diagnosis or anxiety diagnosis) or the date of censoring.  
Statistical analysis 
To ascertain risk we used stratified cox proportional hazards regression for both depression and 
anxiety as outcomes for the group with CP when compared to the matched reference group. 
These were firstly run unadjusted and then adjusted for potential confounders. 
In our stratified analysis we then re-ran all analyses with the CP group stratified by the 
presence of co-morbid ID. For these analyses we compared CPnoID and CP+ID with their 
respective matched reference groups.  Prior to running our analyses we checked the assumption 
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of proportional hazards by plotting scaled Schoenfeld residuals against time for all models, and 
found this assumption was satisfied. All analyses were conducted using STATA 14.0.  
Results 
Descriptive data 
We present descriptive data pertaining to the sociodemographic and health-related 
characteristics of the sample in Table 1. The mean age of the sample was 33.3 and 46.8% of 
both the group with CP and matched controls were female. The data also shows that people 
with CP had a higher frequency of attending the doctor, a higher frequency of epilepsy and a 
higher frequency of pain conditions than the matched controls. 
Risk of depression 
During the follow-up period, there were 1,179 new events of depression following the index 
date. In total, 867 people from the reference group (17.0%) had a new event of depression over 
a median of 9.1 (minimum 0.01 to maximum 28.01) years of follow-up. In total, 312 patients 
with CP (18.3%) had a new event of depression over a median of 5.7 (minimum 0.001 to 
maximum 27.9) years of follow-up (see Table 3). The unadjusted Cox model indicated that 
patients with CP had an increased hazard of depression when compared to matched patients 
without CP (HR 1.43: 95% CI: 1.24-1.64). This association remained significant (HR 1.28: 
95% CI 1.09-1.51) after controlling for other chronic conditions and the average number of GP 
visits (see Table 3). 
After stratifying  for the presence of co-morbid ID in people with CP, we found that 
there were 264 (19.6%) new cases of depression in the CPnoID group over a median of 5.2 
(minimum 0.05 to maximum 27.9) years of follow-up. However, there were 48 (13.3%) new 
cases of depression in the CP+ID group over a median of 7.4 (minimum 0.01 to maximum 
26.1) years of follow-up. When we conducted Cox regression analysis, stratified according to 
presence of ID, we found that the CPnoID group had an increased adjusted hazards of incident 
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depression compared with their matched reference group (adjusted HR 1.44: 95% CI 1.20-
1.72) (see Table 4). For both unadjusted and adjusted analyses, the CP+ID group had no 
difference in their hazard of incident depression when compared to their matched reference 
group (see Table 4). For Kaplan-Meier plots see Appendix C.  
Risk of anxiety 
During the follow-up period, there were 958 new events of anxiety after the index date. 
In total, 697 people from the reference group (13.6%) had a new event of anxiety over a median 
of 9.5 (minimum 0.01 to maximum 28.0) years of follow-up and 261 patients with CP (15.3%) 
had a new event of anxiety over a median of 6.0 (minimum 0.003 to 27.9) years of follow-up 
(see Table 3). The unadjusted hazards ratio indicated an increased risk of anxiety for people 
with CP when compared with the matched reference group (HR 1.40, 95% CI: 1.21-1.63). This 
increased risk persisted after controlling for other chronic conditions and the average number 
of GP visits (HR 1.38: 95% CI 1.15-1.64) (see Table 3).  
After stratifying for co-morbid ID, we found that in the CPnoID group there were 217 
(16.2%) new cases of incident anxiety over a median of 5.6 (minimum 0.003 to maximum 27.9) 
years of follow-up (see Table 3). In the CP+ID group, there were 44 (12.2%) new cases of 
incident anxiety over a median of 7.7 (minimum 0.06 to maximum 26.1) years of follow-up 
(see Table 3). The Cox regression analysis indicated that the CPnoID group had an increased 
adjusted hazards of incident anxiety when compared to their matched reference group (HR 
1.55: 95% CI 1.28-1.87) (see Table 3). However, the CPnoID group had no difference in their 
unadjusted or adjusted hazards of experiencing incident anxiety when compared to their 
matched reference group (see Table 3). For Kaplan-Meier plots see Appendix C.   
Sensitivity analysis 
As a total of 24 participants within the noCP group also had ID which could affect estimates, 
we re-ran all analyses excluding these participants from our ID stratified analyses (see 
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Appendix B). Removal of people with ID from the control group did not have a substantial 
effect on the results (see Appendix B). 
Discussion 
Results from this study indicated that people with CP had an increased risk of being 
diagnosed with depression or anxiety, when compared with a matched control group of adults 
without CP. These results could have been observed because adults with CP present with many 
physiological, psychological, social and health-related risk factors that have been shown to be 
associated with depression and anxiety in the general population such as multimorbidity (27-
29), increased pain (30-32), functional limitations (2, 33), noncommunicable diseases (12, 14, 
34, 35), difficulties with social relationships (36, 37) and poorer sleep (38, 39). Furthermore, 
when we examine work that has been conducted in adults with CP depressive symptoms are 
associated with fatigue (15) and pain (15, 40). However, we need more work to determine why 
people with CP may have a higher risk of depression and anxiety so that we may develop the 
evidence-base for mental health interventions in this population.Our results also indicate that 
ID co-morbidity should be considered when assessing the mental health of adults with CP. We 
found the risk of depression and anxiety was higher in the adults with CP who did not have ID, 
compared with the matched reference group. Furthermore, adults with CP and ID had a similar 
hazards of developing depression and anxiety to the matched reference group. We could have 
observed these results as previous work suggests that diagnostic overshadowing may lead to 
an under diagnosis of mental illness among people who have ID (19) due to the fact that distress 
can present as challenging behaviours  (20, 21). Thus, it is possible that GPs may not be as well 
trained in diagnosing depression and anxiety in these individuals. However, there is also work 
that has been conducted in populations with ID, indicating that the prevalence of anxiety and 
depression in people with ID is no different to the general population (21).  
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While our evidence suggests an increased risk of developing anxiety and depression in 
adults with CP when compared with adults who do not have CP it should be noted that there 
was little difference in absolute risk for developing anxiety or depression over the total follow-
up period. 
This is the first study to examine the risk of depression and anxiety in adults with CP 
to adults who do not have CP using a population-based cohort. The results support previous 
work that shows a relatively high frequency of depression and anxiety in individuals with CP 
(15, 17).  
However, there are limitations that should be borne in mind. Due to the nature of the 
population examined and the reliance on the presence of diagnostic codes to define outcomes, 
there is a possibility that any observed associations are underestimated as previous work 
suggests depression and anxiety diagnoses in primary care may be underestimated (41, 42). 
This could also explain why the rates of depression and anxiety we observed in CP for this 
study were lower than other studies have previously reported (17, 18). Furthermore, CP is an 
umbrella term used to describe heterogeneous etiologies, however we could not account for the 
severity of issues associated with CP. These include gross motor function, communication 
issues, subtypes of motor abnormality, and fatigue. Future work should provide more insight 
into how CP-specific issues might be associated with mental health. In addition, the measure 
of pain conditions that we had within this study relied only on medications. 
There are also additional caveats that should be borne in mind when interpreting these 
data. Depression and anxiety are both considered chronic conditions that typically have their 
first onset in adolescence or early adulthood (43), therefore it is plausible to assume that some 
people may have had diagnoses of depression and anxiety prior to the index date for this study. 
In future work it could be interesting to look at the lifecourse of mental illness in people with 
CP, looking at people from adolescence through to older age. 
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In conclusion, this work provides evidence that adults with CP have an increased risk 
of developing depression and anxiety. Furthermore, co-morbidity of ID is an important effect 
modifier that should be considered when examining the mental health of adults with CP. There 
is a need for more work to elucidate the causal mechanisms of poor mental health in adults 
with CP so that we may develop targeted interventions. 
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Table 1: Characteristics of participants  
 








Age <30 2631 (51.44%) 877 (51.44%) 691 (51.49%) 186 (51.24%) 
 30-39 1008 (19.71%) 335 (19.71%) 252 (18.78%) 84 (23.14%) 
 40-49 669 (13.08%) 223 (13.08%) 172 (12.82%) 51 (14.05%) 
 50-59 405 (7.92%) 135 (7.92%) 108 (8.05%) 27 (7.44%) 
 >=60 402 (7.86%) 134 (7.86%) 119 (8.87%) 15 (4.13%) 
Sex Male 2721 (53.20%) 907 (53.20%) 703 (52.83%) 204 (56.20%) 
 Female 2394 (46.80%) 798 (46.80%) 639 (47.62%) 159 (43.80%) 
Region North  1419 (27.74%) 473 (27.74%) 349 (26.01%) 124 (34.16%) 
 Midlands 1809 (35.37%) 603 (35.37%) 498 (37.11%) 105 (28.93%) 
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 South  1761 (34.43%) 587 (34.43%) 459 (34.02%) 128 (35.26%) 
 Northern 
Ireland 
126 (2.46%) 42 (2.46%) 36 (2.68%) 6 (1.65%) 
Average 
GP visits 
per year  
0-1.9 per year 715 (14%) 133 (7.83%) 123 (9.20%) 10 (2.76%) 




956 (71.50%) 222 (61.33%) 
≥ 12 per year 358 (7.01%) 388 (22.84%) 258 (19.30%) 130 (35.91%) 
Presence 
of: 
Depression  867 (16.95%) 312 (18.30%) 263 (19.60%) 49 (13.50%) 
 Anxiety  697 (13.63%) 261 (15.31%) 216 (16.10%) 45 (12.40%) 
 Diabetes  218 (4.26%) 55 (3.23%) 47 (3.50%) 14 (3.86%) 
 Heart disease  584 (11.42%) 160 (9.38%) 165 (12.30%) 20 (5.51%) 
 Osteoarthritis  320 (6.26%) 87 (5.10%) 90 (6.71%) 15 (4.13%) 
 Epilepsy  49 (0.96%) 354 (20.76%) 216 (16.10%) 155 (42.70%) 
 Lung disease 379 (7.41%) 147 (8.62%) 143 (10.66%) 26 (7.16%) 




This table presents the distribution of the sociodemographic and health-related characteristics 
of patients within the sample. The CP column presents data for all people with CP in the 
sample, the CPno ID and CP+ID columns represent people from the CP column stratified for 
the presence of ID. 
 
CPnoID: Cerebral Palsy with no co-morbid ID 











Table 2: Incidence of depression and anxiety in people with Cerebral Palsy (n=1705) compared with age, sex and practice-matched 
controls (n=5115). 
 
  Events n (%) Person years in 
10,000s 
Incidence per 10,000 
person years 
Unadjusted HR 
(95% CI) and p-
value 
Adjusted HR 
†(95% CI) and p-
value 
Depression No CP  867 (16.95%) 49.93 0.017 (0.016-0.019) 1 1 




Anxiety No CP 697 (13.63%) 51.67 0.013 (0.013-0.015) 1 1 





† Adjusted for baseline (i.e., pre-depression or pre-anxiety diagnosis) diagnosis of diabetes, heart disease, lung disease, osteoarthritis, epilepsy, 





















Table 3: Incidence of depression and anxiety in people with CP with and without co-morbid ID 
 
  Events n (%) Person years 
in 10,000s 




(95% CI) and p-
value 
Adjusted hazards 





reference group  
687 (17.04%) 39.32 0.017 (0.016-0.019) 1 1 







reference group  
180 (16.62%) 10.61 0.017 (0.015-0.020) 1 1 




Anxiety CPnoID Matched 
reference group  
542 (13.44%) 40.72 0.013 (0.012-0.014) 1 1 




Anxiety CP+ID Matched 
reference group  
155 (14.31%) 10.94 0.014 (0.012-0.017) 1 1 





† Adjusted for baseline (i.e., pre-depression or pre-anxiety diagnosis) diagnosis of diabetes, heart disease, lung disease, osteoarthritis, epilepsy, 
pain conditions and GP visits per year. 
 
CPnoID: Cerebral Palsy with no co-morbid ID  
CP+ID: Cerebral Palsy with co-morbid ID. 
 
Each CP group was compared to their respective age, sex and practice matched reference group. CPnoID N=1342 and their respective matched 






































Read codes and associated Read terms used to define Cerebral Palsy 
Read code Read term 
F23y400  Ataxic diplegic cerebral palsy  
F23y000  Ataxic diplegic cerebral palsy  
F137.11  Athetoid cerebral palsy  
F137000  Athetoid cerebral palsy  
F2B..00  Cerebral palsy  
F2Bz.00  Cerebral palsy NOS  
F230100  Cerebral palsy with spastic diplegia  
F23..00  Congenital cerebral palsy  
F23y300  Dyskinetic cerebral palsy  
F23..12  Infantile cerebral palsy  
F23y200  Spastic cerebral palsy  
F230111  Spastic diplegic cerebral palsy  
F2B1.00  Spastic hemiplegic cerebral palsy  
F2B0.00  Spastic quadriplegic cerebral palsy  
F23yz00  Other infantile cerebral palsy NOS  
Fyu9000  [X]Other infantile cerebral palsy  
F23y.00  Other congenital cerebral palsy  
F23y100  Flaccid infantile cerebral palsy  
F2By.00  Other cerebral palsy  
Fyu9.00  [X]Cerebral palsy and other paralytic syndromes 
F23z.00  Congenital cerebral palsy NOS  
F23..11  Congenital spastic cerebral palsy  













Read codes and associated Read terms used to define Depression 
Read Code Read term 
Depression 
Eu32700 [X] Major depression, severe without psychotic symptoms 
Eu32200 [X] Severe depressive episode without psychotic symptoms 
Eu32213 [X] Single episode vital depression without psychotic symptoms 
Eu33214 [X] Vital depression, recurrent without psychotic symptoms 
Eu3y111 [X] Recurrent brief depressive episodes 
E113700 Recurrent depression 
E2B1.00 Chronic depression 
E113200 Recurrent major depressive episodes, moderate 
E113.00 Recurrent major depressive episode 
Eu33100 [X] Recurrent depressive disorder, current episode moderate 
E112.11 Agitated depression 
E135.00 Agitated depression 
Eu32.11 [X] Single episode of depressive reaction 
E112200 Single major depressive episode, moderate 
Eu33211 [X] Endogenous depression without psychotic symptoms 
Eu32.13 [X] Single episode of reactive depression 
E112300 Single major depressive episode, severe, without psychosis 
E112000 Single major depressive episode, unspecified 
Eu33200 [X] Recurrent depressive disorder current episode severe without 
psychotic symptoms 
E112.13 Endogenous depression first episode 
E112.14 Endogenous depression 
Eu33212 [X] Major depression, recurrent without psychotic symptoms 
Eu32212 [X] Single episode major depression without psychotic 
symptoms 
Eu32211 [X] Single episode agitated depression without psychotic 
symptoms 
Eu33000 [X] Recurrent depressive disorder, current episode mild 
E113700 Recurrent depression 
Eu33.11 [X] Recurrent episodes of depressive reaction 
E11y200 Atypical depression disorder 
E113100 Recurrent major depression episodes, mild 
Eu32400 [X] Mild depression 
Eu32z13 [X] Prolonged single episode of reactive depression 
E113.11 Endogenous depression - recurrent 
E112.12 Endogenous depression first episode 
E112.00 Single major depression episode 
E290.00 Brief depressive reaction 
Eu32y11 [X] Atypical depression 
Eu33.13 [X] Recurrent episodes of reactive depression 
E113300 Recurrent major depressive episodes, severe, no psychosis 
Eu33.12 [X] Recurrent episodes of psychogenic depression 
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Eu32.12 [X] Single episode of psychogenic depression 
Eu32600 [X] Major depression, moderately severe 
Eu33.00 [X] Recurrent depressive disorder 
Eu33z00 [X] Recurrent depressive disorder, unspecified 
E291.00 Prolonged depressive reaction 
Eu32500 [X] Major depression, mild 
E112100 Single major depressive episode, mild 
Eu32000 [X] Mild depressive episode 
Eu32.00 [X] Depressive episode 
Eu32z00 [X] Depressive episode, unspecified 
E2B..00 Depressive disorder NEC 
1B17.00 Depressed 
2257 o/e - depressed 
1B1U.11 Depressive symptoms 
1B1U.00 Symptoms of depression 
1B17.11 c/o - feeling depressed 
1BT..00 Depressed mood 
1JJ..00 Suspected depression 
Depression with psychosis 
Eu32800 [X] Major depression, severe with psychotic symptoms 
Eu32313 [x] Single episode of psychotic depression 
Eu33315 [X] Recurrent severe episodes of psychotic depression 
E113400 Recurrent major depressive episodes, severe, with psychosis 
Eu33300 [X] Recurrent depressive disorder current episode severe with 
psychotic symptoms 
E112400 [X] Single major depressive episode, severe, with psychosis 
Eu33314 [X] Recurrent severe episodes/psychogenic depressive psychosis 
Eu33316 [X] Recurrent severe episodes/reactive depressive psychosis 
Eu32311 [X] Single episode of major depression and psychotic symptoms 
Eu32312 [x] Single episode of psychogenic depressive psychosis 
Eu32314 [X] Single episode of reactive depressive psychosis 
E11..12 Depressive psychoses 
Eu32300 [X] Severe depressive episode with psychotic symptoms 
Eu33311 [X] Endogenous depression with psychotic symptoms 
E130.00 Reactive depressive psychosis 
E130.11 Psychotic reactive depression 
Eu33313 [X] Recurrent severe episodes/major depression + psychotic 
symptoms 
Depression other or NOS 
E113z00 Recurrent major depressive episode nos 
Eu33y00 [X] Other recurrent depressive disorders 
Eu32y00 [X] Other depressive episodes 
E113000 Recurrent major depressive episodes, unspecified 
E290z00 Brief depressive episode nos 
Eu32y12 [X] Single episode of masked depression NOS 
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E11z200 Masked depression 
Eu33z11 [X] Monopolar depression NOS 
Eu32z14 [X] Reactive depression NOS 
E112z00 Single major depression episode NOS 
Eu32100 [X] Moderate depressive episode 
Eu32z11 [X] Depression NOS 
Eu32z12 [X] Depressive disorder NOS 
E112.11 agitated depression 
Eu32211 [x]single episode agitated depression w'out psychotic symptoms 
Dysthymia 
Eu34100 Dysthymia 
Eu34112 [X] Depressive personality disorder 
E211200 Depressive personality disorder 
Eu34111 [X] Depressive neurosis 
Eu34113 [X] Neurotic depression 
E204.00 Neurotic depression reactive type 
Mixed depression anxiety 
Eu41200 [X]Mixed anxiety and depressive disorder 
Eu41211 [X]Mild anxiety depression 
E200300 Anxiety with depression 
Eu34114 [X] Persistant anxiety depression 
Secondary depression 
E204.11 Postnatal depression 
Eu53011 [X] Postnatal depression NOS 
Eu32B00 [X] Antenatal depression 
E001300 Presenile depression with dementia 
E002100 Senile dementia with depression 
Eu53012 [X] Postpartum depression nos 
Eu02z16 [X] Senile dementia, depressed or paranoid type 
E002.00 Senile dementia with depressive or paranoid features 
R007z13 [d] postoperative depression 
E002z00 Senile dementia with depressive or paranoid features NOS 
62T1.00 Puerperal depression 
E004300 Arteriosclerotic dementia with depression 
Eu20400 [x] Post-schizophrenic depression 
E02y300 Drug-induced depressive state 
Eu92000 [X] Depressive conduct disorder 
Eu33.15 [X] SAD- seasonal affective disorder 
E118.00 Seasonal affective disorder 
Eu33.14 [X] Seasonal depressive disorder 
Therapy 
8CAa.00 Patient given advice about management of depression 






Drugs used to identify possible depression (to be considered a case of depression 
patients were required to also have one of the read codes indicative of possible 
depression) 
Antidepressants   
Dosulepin   
Imipramine   
Lofepramine   
Nortriptyline   
Trimipramine   
Amoxapine   
Dothiepin   
Maprotiline   
Mianserin   
Trazadone 
Antidepressants (MAOIs) 
  Phenelzine   
Isocarboxazid   
Tranlcypromine   
Moclobemide 
Antidepressant (SSRI)   
Citralopram   
Fluoxetine   
Fluvoxamine   
Paroxetine   
Sertraline   
Escitalopram 
Antidepressant (other)   
Flupentixol   
Mirtazapine   
Reboxetine   
Venlafaxine   
Tryptophan   
Agomelatine   
Duloxetine 
 
Read codes and associated Read terms used to define possible depression.  
Read code Read term 
1BT..11 Low mood 
1B1J.11 Emotional upset 
16ZB100 feeling low or worried 
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7899 o/e - distressed 
E205.11 nervous exhaustion 
E20z.11 nervous breakdown 
E290011 bereavement reaction 
E290000 Grief reaction 
8HHK.00 referral to bereavement counsellor 
IBT..12 sad mood 
1BT..11 Low mood 
Eu3z.00 [X] Unspecified mood affective disorder 
Eu05300 [X] Organic mood [affective] disorders 
Eu34z00 [X] Persistant mood affective disorder, unspecified 
Eu34.00 [X] Persistant mood affective disorders 
Eu34y00 [X] Other persistant mood affective disorders 
Eu3..00 [X] Mood - affective disorders 
Eu3y.00 [X] Other mood affective disorders 
Eu3y100 [X] Other recurrent mood affective disorders 
Eu3y000 [X] Other single mood affective disorders 
Eu3yy00 [X] Other specified mood affective disorders 





















Read codes and associated Read terms used to define Anxiety Disorders 
Anxiety disorders were defined as generalised anxiety disorder, mixed depression and anxiety 
disorder, panic disorder or phobias. As obsessive-compulsive disorders and post-traumatic and acute 
stress disorders are no longer considered anxiety disorders within the DSM-V we opted to exclude 
these events as cases of anxiety. 
Read code Read term 
Mixed depression anxiety 
Eu41200 [X]Mixed anxiety and depressive disorder 
Eu41211 [X]Mild anxiety depression 
E200300 Anxiety with depression 
Eu34114 [X] Persistant anxiety depression 
Anxiety disorder diagnoses 
Eu41.00 [x] other anxiety disorders 
Eu40y00 [x]other phobic anxiety disorders 
Eu41000 [x]panic disorder [episodic paroxysmal anxiety] 
Eu40012 [x] panic disorder with agoraphobia 
1B1V.00 c/o - panic attack 
Eu41011 [x] panic attack 
225J.00 o/e - panic attack 
E200111 panic attack 
Eu41100 [x]generalized anxiety disorder 
Eu41300    [X]Other mixed anxiety disorders 
Eu41y00    [X]Other specified anxiety disorders 
Eu41z00 [x]anxiety disorder, unspecified 
Eu05400 [x]organic anxiety disorder 
E2000000    Anxiety state unspecified 
Eu41113 [x] anxiety state 
E200100 panic disorder 
Eu41100 [X] Generalized anxiety disorder 
E200200   Generalised anxiety disorder 
Eu41111 [x] anxiety neurosis  
E200400 Chronic anxiety 
E200500 Recurrent anxiety 
E200.00 anxiety states 
E200z00 anxiety state nos 
Eu41z11 [x] anxiety nos 
E292000 Separation anxiety disorder 
Eu93000 [x] separation anxiety disorder to childhood 
E2D0000 childhood and adolescent overanxiousness disturbance 
E2D0.00 disturbance of anxiety and fearfulness childhood/ 
adolescent 
E2D0z00 disturbance anxiety and fearfulness 
childhood/adolescent nos 
Eu93y12 [x] childhood overanxious disorder 
29 
 
Eu41112 [x] anxiety reaction 
1B13.00 anxiousness 
2258 O/E - anxious 
1B13.12 anxious 
8G94.00 anxiety management training 
8HHp.00 referral for guided self-help for anxiety 
Z481.00 phobia counselling 
8CAZ000 patient given advice about management of anxiety 
8G52.00 antiphobic therapy 
1B13.11 anxiousness - symptom 
Z4I7.00 acknowledging anxiety 
Z4I7100 recognising anxiety 
Eu41012 [x]panic state 
Eu41112 [x] anxiety reaction 
Phobias 
Eu40000 [x]agoraphobia 
Eu40011 [x]agoraphobia without history of panic disorder 
E202100 agoraphobia with panic attacks 
E202200 agoraphobia without mention of panic attacks 
Eu40200 [x] specific (isolated) phobias 
Eu40214 [x] simple phobia 
E202700 animal phobia 
E202C00 dental phobia 
Eu40212 [x]animal phobias 
E28z.12 flying phobia 
E202A00 Fear of flying 
E202E00 Fear of pregnancy 
Eu40213 [x] claustrophobia 
E202800 claustrophobia 
Eu40300 [x]needle phobia 
E202600 acrophobia 
E202D00 Fear of death 
Eu40100 [x]social phobias 
E202400 social phobia, fear of public speaking 
E202B00 cancer phobia 
E202300 social phobia, fear of eating in public 
E202500 social phobia, fear of public washing 
E202.11 social phobic disorders 
Eu93200 [x] social anxiety disorder of childhood 
Eu93100 [x] phobic anxiety disorder of childhood 
Eu45215 [x]nosophobia 





Eu40z11 [x]phobia nos 
E202.00 phobic disorders 
E202z00 phobic disorder nos 
E202.12 phobic anxiety 
Eu40z00 [x] phobic anxiety disorder, unspecified 
E202000 Phobia unspecified 
Eu40y00 [x] other phobic anxiety disorders 
Eu40.00 [x] phobic anxiety disorders 
E292000 separation anxiety disorder 





























Drugs used to identify possible anxiety (to be considered a case of anxiety patients were 
required to also have one of the read codes indicative of possible anxiety) 
 
Anxiolytics   
Diazepam   
Alprazolam   
Bromazepam   
Chlordiazepoxide   
Chlorezanone   
Clobazem 
  Clorazepate dipotassium 
  Hydroxyzine hcl (anxiolytic) 
  Ketazolam - discontinued 
  Lorazepam (anxiolytic) 
  Medazepam - discontinued 
  Meprobamate 
  Oxazepam 
SSRIs  Citralopram 
  Fluoxetine 
  Fluvoxamine 
  Paroxetine 
  Sertraline 
  Escitalopram 
 
Read codes and associated Read terms used to define possible anxiety. 
Read code Read term 
1B12.00 Nerves' -  nervousness 
R2y2.00 (d) nervousness 
R2y2. O/E nervous 
1B12.12 tension - nervous 
R2y2.12 [d] nervous tension 
E205.11 nervous exhaustion 
E20z.11 nervous breakdown 
1B1..00 general nervous symptoms 
1B1Z.00 general nervous symptoms nos 
2253 o/e - distressed 







Risk of depression and anxiety in people with CP with and without co-morbid ID (excluding all people without CP who had a diagnosis 
of ID, n=24). 
 
  Events n (%) Person years 
in 10,000s 




(95% CI) and p-
value 
Adjusted hazards 





reference group  
684 (17.02%) 39.22 0.017 (0.016-0.019) 1 1 







reference group  
177 (16.50%) 10.54 0.017 (0.014-0.019) 1 1 




Anxiety CPnoID Matched 
reference group  
540 (13.44%) 40.61 0.013 (0.012-0.014) 1 1 




Anxiety CP+ID Matched 
reference group  
152 (14.17%) 10.87 0.014 (0.012-0.016) 1 1 





† Adjusted for baseline (i.e., pre-depression or pre-anxiety diagnosis) diagnosis of diabetes, heart disease, lung disease, osteoarthritis, epilepsy, 
pain conditions and GP visits per year. 
 
CPnoID: Cerebral Palsy with no co-morbid ID  




Each CP group was compared to their respective age, sex and practice matched reference group. CPnoID N=1342 and their respective matched 

































Appendix C: Kaplan Meier survival plots 
 
Comparison of all people with CP (n=1,705) and all matched controls (n=5,115) 
 
Graph i: Time to depression for people with CP and matched-controls 
 
 







Comparison of CPnoID (n=1,342) with respective matched controls (n=4,026) 
 
Graph iii: Time to depression for people with CPnoID and respective matched-controls 
 
 








Comparison of CP+ID (n=363) with respective matched controls (n=1,089) 
 




Graph vi: Time to anxiety for people with CP+ID and respective matched-controls 
 
 
 
 
